Polycythemia Vera & Myelofibrosis Treatment | Jakafi (ruxolitinib)
Jakafi (ruxolitinib) is an FDA-approved treatment for intermediate or high-risk myelofibrosis and polycythemia vera that inhibits JAK1, & JAK2 & improves symptoms & splenomegaly.
Jakafi (ruxolitinib), myelofibrosis treatment, treatment for myelofibrosis, intermediate risk myelofibrosis, high risk myelofibrosis, polycythemia vera, pv, polycythemia treatment, treatment for pv, JAK pathway, JAK2V617F mutation, jakafi.com
Is this your site? Certify your site and update informations
